Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15566802 | 0.86 | TRPM8 (0.63) | TRPM8PDE2ACFTR | |
| SCHEMBL15566800 | 0.86 | TRPM8 (0.63) | TRPM8PDE2ACFTR | |
| SCHEMBL16418808 | 0.84 | TRPM8 (0.46) | TRPM8RAB9ANPC1LMNASMN1; SMN2 | |
| Formic Acid SCHEMBL16414127 | 0.84 | TRPM8 (0.59) | TRPM8PDE2ACFTR | |
| Formic Acid SCHEMBL16414125 | 0.84 | TRPM8 (0.59) | TRPM8PDE2ACFTR | |
| SCHEMBL16418806 | 0.83 | TRPM8 (0.46) | TRPM8RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL16418803 | 0.83 | TRPM8 (0.46) | TRPM8RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15469394 | 0.83 | TRPM8 (0.46) | TRPM8RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL15467345 | 0.83 | TRPM8 (0.53) | TRPM8RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL15467342 | 0.83 | TRPM8 (0.53) | TRPM8RAB9ANPC1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885RAB9A 1056/4885PDE2A 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.